| HS Code | 870306 |
| Product Name | Eye Drops Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Product Category | Veterinary Grade Active Pharmaceutical Ingredient (API) |
| Target Species | Dogs, cats, horses, cattle, swine, sheep, goats, and other veterinary species |
| Therapeutic Function | Active ingredient intended for ophthalmic and systemic veterinary formulations |
| Available Dosage Forms For Formulation | Eye drops, tablets, injections, capsules, powders, granules, premix, solutions |
| Route Of Administration | Ophthalmic, oral, parenteral, or in-feed/in-water administration depending on finished dosage form |
| Physical Appearance | White or off-white crystalline powder or granules |
| Solubility Profile | Soluble in suitable aqueous and organic solvents depending on specific salt or derivative |
| Potency Assay | Assay typically 95.0% to 101.0% on dried basis per applicable veterinary monograph |
| Purity Specifications | Meets prescribed limits for related substances, residual solvents, heavy metals, and microbial contamination |
| Quality Standards | Complies with veterinary pharmacopoeial standards such as USP, Ph.Eur., or BP |
| Manufacturing Process | Manufactured through controlled synthesis and purification under current Good Manufacturing Practice (cGMP) |
| Shelf Life | Typically 24 to 60 months from date of manufacture when stored correctly |
| Storage Conditions | Store in tightly closed, light-resistant containers in a cool, dry, well-ventilated area |
| Packaging | Sealed polyethylene liner inside fiber drum or aluminum laminated bag |
| Regulatory Documentation | Supplied with certificate of analysis, stability summary, GMP certificate, and safety data sheet |
As an accredited Eye Drops Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Supplied in sealed polyethylene-lined bags inside fiber drums, 25 kg net per drum, with tamper-evident closure and compliant labeling. |
| Container Loading (20′ FCL) | Pallets of sealed, labeled containers are loaded into a 20-foot FCL, securing the veterinary-grade API for safe transport. |
| Shipping | Ship as a veterinary-grade active pharmaceutical ingredient (API), not as finished eye drops. Use clean, sealed, UN-approved packaging suitable for powders or solutions. Label: “Veterinary API – For Manufacturing Use Only.” Protect from moisture, heat, and light. Attach SDS and certificate of analysis. Confirm local transport regs; classify as non-hazardous unless SDS indicates otherwise. |
| Storage | Store in tightly sealed, moisture-proof containers in a cool, dry, well-ventilated area at controlled room temperature (20–25°C). Protect from light, humidity, and extreme heat. Keep away from incompatible materials and foodstuffs. Ensure containers are clearly labeled and securely closed to prevent contamination, degradation, or microbial growth. |
| Shelf Life | Shelf life is typically 24–36 months when stored as directed in original sealed containers, protected from light and moisture. |
In aseptic ophthalmic solution manufacturing, the API supplied as a sterile micronized powder is reconstituted into water for injection under nitrogen blanketing; the first process decision is whether the formulation target is a solution or a preservative-free suspension, because the chemical form received for ophthalmic use may have a particle size distribution with D90 <25 µm and bulk density of 0.35–0.55 g/cm³. The addition ratio is set by the target ophthalmic dose and eye geometry rather than by a fixed bulk formula: solution concentrations are typically between 0.1% w/v and 1.0% w/v, while suspension formulations may reach 1.5% w/v for sustained ocular retention, with final tonicity adjusted to 290–310 mOsm/kg using sodium chloride or mannitol per Ph. Eur. 2.2.35 and pH buffered to 6.5–7.5 with phosphate or citrate buffer. Sterility assurance for multi-dose ophthalmic formulations is evaluated under Ph. Eur. 2.6.1 and USP <71>; preservative efficacy testing follows Ph. Eur. 5.1.3 or USP <51>, and aseptic processing validation follows ISO 13408-1:2016 with 21 CFR 210/211 operating discipline. The terminal filling process is conducted in an ISO 14644-1 class 7 background with Grade A critical zones, often using a blow-fill-seal or aseptic cartridge-needle line operating at 12,000–18,000 containers/hour; the most frequent production deviation is not sterility failure but dimensional variation in LDPE neck geometry after warm-fill dosing at 28–32°C, where insufficient nozzle dwell below 0.4 seconds leads to neck ovality above 0.3 mm and interference with tamper-evident cap torque. Filter integrity is tested before and after each batch with a bubble-point threshold of 3.2–3.8 bar for 0.22 µm PVDF membranes; a pre-filtration colloid load above 5 NTU from inadequate dissolution is a leading cause of filter flux collapse. Terminal finished product types include single-dose twist-off LDPE vials, multi-dose dropper bottles with tamper-evident overcaps, and preservative-free unit-dose pipettes used in canine and feline ocular infection, corneal ulcer, or pre-surgical disinfection protocols.
| Parameter | Standard / clause | Acceptance criterion |
|---|---|---|
| Sterility | Ph. Eur. 2.6.1 / USP <71> | No growth after 14 days |
| Bacterial endotoxins | Ph. Eur. 2.6.14 / USP <85> | <0.25 EU/mg |
| Particulate matter | USP <789> / Ph. Eur. 2.9.19 | ≥10 µm: ≤50/mL; ≥25 µm: ≤5/mL |
| Osmolality | Ph. Eur. 2.2.35 | 290–310 mOsm/kg |
| Preservative efficacy | Ph. Eur. 5.1.3 / USP <51> | Bacteria ≥1.0 log reduction at 7 days; no increase at 28 days |
| Container/closure integrity | USP <1207> | No positive leak at defect size 20 µm |
Injectable-grade solutions containing the API are formulated as aqueous vehicle systems in which the active is dissolved at 0.2% w/v to 2.0% w/v after pH adjustment to 5.8–6.8; unlike the ophthalmic solution, the injectable form uses a phosphate-free buffer whenever intramuscular administration in food-producing animals is validated, because phosphate complexes with divalent cations in muscle tissue can delay absorption and increase injection-site residue. Pre-filtration bioburden is controlled to <10 CFU/100 mL before membrane passage, and the final sterilizing filter is a 0.22 µm PVDF or PES cartridge validated per USP <71> and Ph. Eur. 2.6.1. Endotoxin limits for parenteral products follow USP <85> and Ph. Eur. 2.6.14, with acceptance criteria of <0.5 EU/mg for small-volume vials and <0.2 EU/kg of body weight for large-volume bovine injections; depyrogenation is performed in a hot-air tunnel at 250°C for 45 minutes or in a washing cycle that achieves a 3-log endotoxin reduction. The terminal sterilization cycle is validated with steam autoclave cold-spot mapping and biological indicators; typical cycles require 121°C for 15 minutes with an F0 of >15 minutes, but vial neck geometry influences heat penetration because narrow-neck 50 mL borosilicate vials can retain non-condensable gases in the shoulder region if the pre-vacuum pulse drops below −0.85 bar. Production-scale monitoring on multi-purpose autoclave lines has repeatedly associated batch endotoxin excursions with stopper washing water conductivity above 1.3 µS/cm and residual moisture at the vial mouth following washing, rather than with the incoming API. Aseptic filling is used for thermolabile solutions; in that case the fill line is limited by fill-volume accuracy at small volumes, because a 10 mL fill target with ±1% tolerance requires peristaltic pump calibration against density every 60 minutes at sustained line speeds above 20,000 units/hour. Terminal finished product types include 20 mL, 50 mL, and 250 mL multi-dose injection vials for cattle, pigs, and horses, as well as single-dose ampoules packaged in barrier film trays for companion-animal emergency use.
For thermolabile injectable applications, the API is lyophilized into a sterile cake rather than held in aqueous solution, because hydrolysis in phosphate-buffered media above 8°C can reduce assay by more than 2% over 24 hours; lyophilization is therefore selected for daily reconstitution protocols in ambulatory equine and exotic practice. The formulation addition ratio in the pre-lyo bulk is typically 1% w/v to 10% w/v active, with mannitol or glycine as bulking agent at 2–5% w/v and collapse-temperature modifiers included to prevent cake shrinkage. Compliance for sterile powder for injection follows Ph. Eur. 2.6.1, USP <1>, and bacterial endotoxin limits under USP <85> and Ph. Eur. 2.6.14, with reconstitution time and visible particulate matter evaluated per Ph. Eur. 2.9.19. The freeze-drying cycle is run on a shelf lyophilizer with a freezing ramp at −40°C for 4–6 hours, primary drying at shelf temperature −20°C to −10°C and chamber pressure 0.15–0.25 mbar for 18–24 hours, and secondary drying at 25–30°C until cake moisture is <1.0%; the most common production failure is microcollapse at the vial base due to product temperature exceeding the collapse temperature by more than 2°C during primary drying. Terminal finished product types include single-dose amber vials containing 25 mg to 250 mg active per vial, packaged with diluent ampoules in PVC-free blister trays; the label specifies discard after 6 hours post-reconstitution to avoid potency loss and microbial growth.
Because the micronized grade supplied for ophthalmic and parenteral use has a particle size distribution with D90 <25 µm and a bulk density of 0.35–0.55 g/cm³, direct compression of the API into chewable tablets is rarely achievable above 10% w/w active loading without significant weight variability. Such powders often exhibit a Carr’s Index of 25–38 and Hausner ratio of 1.28–1.45, exceeding the direct-compression flow window of <20 and <1.25 recommended for rotary tablet presses and forcing the formulation into wet granulation or roller compaction. The active addition ratio is expressed per core rather than as a fixed percentage: veterinary oral tablets typically contain between 5 mg and 300 mg of API per tablet, corresponding to 1% w/w to 25% w/w of final core mass after blending with lactose monohydrate, microcrystalline cellulose, crospovidone, and sodium stearyl fumarate. Direct compression is validated only when the API loading is below 10% w/w and the press is fitted with a power-assisted feed frame; production-scale trials on a 45-station rotary press at 70,000–90,000 tablets/hour have shown that low-density API fines can fluidize above the die table and increase weight variability to >3% unless a vacuum-assisted feed shoe is used. At compression force of 8–15 kN, ejection force on unlubricated API-lactose blends can exceed 1,500 N, causing die binding and punch scoring; addition of 0.5–1.0% w/w sodium stearyl fumarate reduces ejection force below 900 N without the magnesium stearate over-blending penalty. Wet granulation with a high-shear mixer and fluid-bed dryer remains the more controlled route for higher loadings: the API is granulated with polyvinylpyrrolidone binder added at 2–5% w/w of dry granulate, water addition is controlled to 18–22% w/w, and drying is stopped at a loss-on-drying of 1.5–2.5% and product temperature below 45°C to protect thermolabile impurities. Tablet hardness is specified at 60–100 N, friability at <1.0% per Ph. Eur. 2.9.7, and content uniformity at <6.0% relative standard deviation per USP <905>; tablet dissolution is tested in 900 mL of pH 6.8 phosphate buffer according to Ph. Eur. 2.9.3. Terminal finished product types include uncoated scored tablets for weight-adjusted dosing, chewable meat-flavored tablets for companion animals, and film-coated tablets for swallowing in large-breed dogs.
Encapsulation of the API into hard capsules is governed by the same content-uniformity expectation as tablets under USP <905> and Ph. Eur. 2.9.5, but the controlling parameter shifts from tablet press compactibility to in-die powder bed consolidation because filling accuracy is more sensitive to hopper bed height than to auger speed. The addition ratio for capsules is set by the intended species dose; finished fill masses normally contain 0.5% w/w to 10% w/w active, with absolute active content per capsule between 5 mg and 100 mg after geometric dilution with pregelatinized starch or microcrystalline cellulose. On an intermittent-motion encapsulation machine operating at 120,000 capsules/hour, a 2–4 mm change in tamping pin penetration depth can shift fill weight by 8–12% because the micronized API forms low-porosity slugs at tamping forces above 200 N unless the excipient blend includes 0.3–0.8% w/w colloidal silicon dioxide to improve powder re-fill. Static charge accumulation in low-humidity environments below 30% RH is a production-scale cause of short-fill rejects; blending and encapsulation suites are therefore maintained at 40–50% RH with grounded metal contact surfaces and ionizing bars at the capsule hopper. Weight sorting is performed with a checkweigher at a rejection tolerance of ±3% of target, metal detection follows with a stainless-steel test sphere of 1.0 mm, and 21 CFR 211.110 sampling is used for in-process fill weight. Terminal finished product types include hard gelatin capsules of sizes 3, 2, and 1 for oral administration to dogs and cats, as well as hydroxypropyl methylcellulose capsules for halal and vegetarian market requirements in export destinations.
For flock and herd medication through drinking water, the API is formulated as a soluble powder or effervescent granule with a carrier system selected to prevent caking after bag opening in high-humidity poultry houses; the active concentration in the intermediate powder is normally 10% w/w to 50% w/w, and the field dilution into drinking water is adjusted to 0.01% w/v to 0.05% w/v depending on species and prescription. Compliance for this delivery route follows the relevant veterinary medicinal product monograph for oral solutions and the prudent-use framework, with microbial limits per Ph. Eur. 2.6.12 and 2.6.13 for water-dispensed products; in markets where the product is classified as a medicated feed or water additive, EU 2019/4 and VICH GL18 bioequivalence expectations apply. Granulation is performed in a fluid-bed spray granulator with inlet air at 55–65°C and a spray rate of 50–80 g/min per kg of batch; lactose, citric acid, sodium bicarbonate, and maltodextrin are common carriers, with sodium bicarbonate content limited to 15% w/w to avoid pH above 7.8 in the final solution. A venturi proportioner set at 1:100 or 1:128 is used to meter a stock solution at 20–40 g/L into the drinking line, but the main field failure mode is precipitation when hard water contains calcium above 120 mg/L; addition of a chelating agent such as EDTA at 0.05–0.2% w/w of the final diluted solution is required in such cases, and published data for this specific configuration is limited. Terminal finished product types include single-dose water-soluble sachets of 10 g to 100 g, bulk buckets with silica-gel desiccant inserts, and twin-chamber effervescent tablets dissolved in stock tanks for automatic proportioner lines.
Medicated premix production for feed mills uses a two-stage geometric dilution sequence because direct addition of the API at less than 1 kg/tonne into a 500 kg horizontal paddle mixer routinely leads to blend uniformity coefficients above 8% at the mixer discharge. The API is first preblended with a carrier such as ground corn cob, rice hull, or lactose to form a premix at 1% w/w to 10% w/w active; this premix is then incorporated into complete feed at 0.2 kg/tonne to 2.0 kg/tonne final feed, depending on species and target mill inclusion. Regulatory compliance for medicated feed premises follows 21 CFR 225 and 226 in the United States, EU 2019/4 for feed hygiene and category classification, and ISO 6497:2002 for feed sampling; carryover and sequence verification require flush materials that are tested for active carryover below 1% of the previous batch. A key process conflict arises when the premix is diluted into mash feeds that later pass through a pellet mill conditioner at 70–85°C for 15–30 seconds; the conditioner steam addition increases moisture from 12% w/w to 16–18% w/w and can accelerate hydrolytic degradation of moisture-sensitive API forms whenever post-pellet cooling is delayed beyond 10 minutes. Production-scale monitoring shows that the use of 0.5–1.5% w/w mineral oil as a dust-control and segregation binder reduces API assay variance in bulk silo draw-off from 10.2% to 4.1% relative standard deviation, though published data for this specific configuration is limited. Terminal finished product types include loose meal premix in 25 kg multi-wall bags, pelleted medicated feed for swine and poultry, and extruded feed intermediates for aquaculture lines.
Competitive Eye Drops Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Veterinary ophthalmic dosage forms impose simultaneous constraints on an active pharmaceutical ingredient: low subvisible particulate burden, controlled bacterial endotoxin, narrow particle-size distribution for suspension uniformity, and compatibility with aqueous, non-aqueous, and semi-solid formulations. The multi-dosage-form grade designated VET-API-OPH/07 is released under a compendial control strategy derived from Ph. Eur. 5.1.4, USP <85>, USP <788>, USP <789>, VICH GL18, and ICH Q3D. Its standard release profile includes an assay of 98.0–102.0% on dried basis, total related substances ≤1.0%, residual moisture ≤0.5%, total aerobic microbial count ≤100 CFU/g, and yeast/mould count ≤20 CFU/g. The grade is processed into tablets, injections, capsules, powders, granules, premix, and solutions; for ophthalmic and injectable routes the endotoxin limit is tightened to <0.25 EU/mg, and subvisible particulate matter is controlled to meet USP <789> for ophthalmic solutions and USP <788> for parenterals. The product is intended as a starting material for licensed veterinary finished dosage forms rather than as a sterile ready-to-administer solution.
The difference is not limited to certificate-of-analysis documentation. Uncontrolled veterinary API powders may present broad particle-size distributions, undefined polymorph ratios, and endotoxin levels acceptable for oral granules or feed premixes but incompatible with parenteral or ophthalmic administration. VET-API-OPH/07 is manufactured under a documented change-control system with batch-to-batch particle-size monitoring by laser diffraction according to ISO 13320:2020. The ophthalmic/injectable grade is micronized or air-jet milled to a D90 ≤20 µm, while technical intermediates may retain aggregates above 75 µm. Residual solvent levels are controlled against VICH GL18; the data package includes a nitrosamine risk assessment and elemental impurity data aligned to ICH Q3D. The product is tested for pyrogens with the limulus amebocyte lysate method and released with an endotoxin limit of <0.25 EU/mg for injectable and ophthalmic applications. Conventional oral or premix grades may allow ≥5.0 EU/mg. This distinction prevents the use of the same bulk powder for sterile filtration and for feed additive dilution without re-qualification.
| Attribute | VET-API-OPH/07 | Conventional veterinary API | Technical intermediate |
|---|---|---|---|
| Bacterial endotoxin | <0.25 EU/mg | 2.5–10 EU/mg | Not controlled |
| Subvisible particulates | USP <788> / USP <789> | Not tested | Not tested |
| Particle size D90 | ≤20 µm | 50–150 µm | Variable |
| Residual solvents | VICH GL18 | ICH Q3C only | Not controlled |
| Bioburden TAMC | ≤100 CFU/g | ≤1000 CFU/g | Not controlled |
| Data package | Full CMC, stability, TSE/BSE, nitrosamine assessment | Basic certificate of analysis | Certificate of analysis only |
For tablets, capsules, and premix formulations, the API is released with a loss on drying value of ≤0.5% after drying at 105°C to constant mass. Bulk density is maintained at 0.35–0.55 g/mL, tap density at 0.45–0.70 g/mL, and Carr index at 15–25%, indicating acceptable flow for direct compression and roller compaction. The solid-state form is identified by X-ray powder diffraction; the diffractogram is compared against a working polymorph standard. Differential scanning calorimetry is used to detect the melting endotherm onset, which is controlled within a defined interval. Particle-size distribution is determined by laser diffraction with a Malvern Mastersizer 3000 equipped with an Aero S dry dispersion unit at 1.5 bar; release limits for ophthalmic suspension grades are D10 2–5 µm, D50 8–15 µm, and D90 ≤20 µm. Specific surface area by BET is 3–8 m²/g, which reduces the risk of content non-uniformity in low-dose tablets.
| Parameter | Release limit | Method |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual / Ph. Eur. 2.2.1 |
| Identification | XRPD pattern and IR spectrum match reference | Ph. Eur. 2.2.24 / USP <941> |
| Assay | 98.0–102.0% | HPLC with UV detection |
| Total related substances | ≤1.0% | HPLC |
| Loss on drying | ≤0.5% | Ph. Eur. 2.2.32 |
| Bulk density | 0.35–0.55 g/mL | USP <616> Method 1 |
| Tap density | 0.45–0.70 g/mL | USP <616> Method 2 |
| Particle size D90 | ≤20 µm | ISO 13320:2020 |
| Bacterial endotoxin | <0.25 EU/mg | USP <85> |
| TAMC / TYMC | ≤100 CFU/g / ≤20 CFU/g | Ph. Eur. 5.1.4 |
| Heavy metals | ≤20 ppm | ICH Q3D risk assessment |
| Residual solvents | Class 1 not detected; Class 2 ≤0.1% | VICH GL18 |
| Sterility | Not sterile unless ordered; tested if sterile claim | USP <71> |
Batch release includes quantitative HPLC assay against a reference standard calibrated to a secondary working standard with a response factor relative standard deviation ≤2.0% over six injections. Forced-degradation studies are performed under acidic, alkaline, oxidative, thermal, and photolytic conditions; the mass balance from stress studies is maintained at 95–105% unless a declared degradation product is observed. Long-term stability is conducted at 25°C/60% RH and accelerated stability at 40°C/75% RH in closures simulating the intended packaging. A polymorph screen by X-ray powder diffraction is included at release and after stress; a shift in diffractogram pattern requires new qualification for ophthalmic suspension formulations. The analytical method is validated for specificity, linearity over 80–120% of target concentration, and accuracy with recovery 98–102%.
In tablet and capsule manufacturing, the API is typically dry-blended in a twin-shell V-blender at 25 rpm for 20 min; batch-to-batch variation in bulk density is reduced by pre-sieving through a 500 µm mesh. For wet granulation, the product should be incorporated after the binder solution is cooled to below 30°C if the API exhibits thermolability. Roller compaction is preferred for moisture-sensitive formulations, with roll force 8–12 kN/cm and gap 1.5–2.5 mm. For injections and ophthalmic solutions, the API is dissolved in Water for Injection at pH adjusted to 6.5–7.5; dissolution is aided by a high-shear mixer at 1500 rpm. The bulk solution is passed through a 0.22 µm PVDF filter. Tablet formulations that require extended release may be prepared by direct compression with hypromellose grades; dissolution testing is conducted in 900 mL of pH 6.8 phosphate buffer using USP Apparatus 2 at 50 rpm. If the API is poorly water-soluble, particle-size reduction to D90 <5 µm is necessary to achieve dissolution at Q=80% in 30 min; this requirement is more stringent for ophthalmic suspensions than for oral tablets. Capsule fill weight is monitored by in-line near-infrared analysis, and segregation potential is evaluated using a sampling thief at 10 locations across the blender with acceptance RSD ≤5%.
Ophthalmic formulations require tonicity adjustment to 290–310 mOsm/kg with sodium chloride or mannitol, and viscosity is maintained at 15–35 mPa·s with a cellulose derivative when a viscous drop is required. Ophthalmic suspensions use the micronized API with D90 <10 µm dispersed in a sterile vehicle using a high-shear rotor-stator at 10,000 rpm for 10 min. The vehicle is filtered through a 0.2 µm membrane; if the API is insoluble, it is aseptically added after vehicle sterilization. Zeta potential should be below −20 mV or above +20 mV to prevent flocculation. Injectable solutions are tested for subvisible particles using a light obscuration particle counter with a 4 mL sample volume; if the average count exceeds the monograph limit, the batch is rejected.
Powders, granules, and premix forms are prepared by dispersing the API onto a feed-grade carrier by stepwise mixing. Because the product has a narrow particle-size distribution, it may segregate if mixed with large carrier particles; this is mitigated by using a carrier with a D50 150–250 µm. The premix is filled into multilayer paper bags with a polyethylene liner and stored at 15–25°C. Solutions for drench or drinking water are prepared at a concentration determined by the intended dose; solubility at the target pH must be confirmed because precipitation can occur below pH 4.0 if the API is a weak acid or above pH 8.0 if it contains base-labile groups. On production-scale lines, the primary processing bottleneck is the transfer of micronized powder into the compounding vessel under low-humidity conditions. If the API is not conditioned at 18–25°C and ≤40% RH, electrostatic charging causes adhesion to stainless steel and reduces yield by as much as 5%. A loss-in-weight feeder with 0.1% accuracy is used for tablet compression; pre-compression force 5.0 kN and main compression force 15–25 kN are typical for tablets containing 50–200 mg of API.
If the API is thermolabile, terminal sterilization by moist heat at 121°C for 15 min may not be feasible. In this case, the manufacturing process is designed as an aseptic fill. The bulk solution is compounded in a closed vessel under ISO 14644-1:2015 Class 5 conditions and filter-sterilized through two 0.22 µm PVDF membrane filters in series. The receiving vessel, filling lines, and containers are sterilized by dry heat at 250°C for 30 min or saturated steam at 122°C for 30 min. Blow-fill-seal lines are operated with unidirectional airflow at 0.45 m/s ±20% and are monitored for non-viable particles to ISO 14644-1:2015. Personnel access follows EU Annex 1; environmental monitoring includes settle plates, active air sampling, and contact plates.
The API is not released as sterile by default; a sterile claim requires terminal gamma irradiation at 25 kGy with subsequent sterility testing per USP <71> and endotoxin retesting per USP <85>. If the API is irradiated, the diffraction pattern and assay must be revalidated because free radicals generated during irradiation can alter the solid-state form or produce degradation products. For injectable dosage forms, particulate matter is tested by light obscuration per USP <788>; for ophthalmic solutions, the corresponding method is USP <789>.
Storage is in double polyethylene bags inside an aluminium-laminated foil pouch, with a nitrogen overlay and desiccant. The sealed package is placed in a fibreboard drum with a tamper-evident seal. Under these conditions, retest date is assigned at 24 months when stored below 25°C and ≤40% RH. Gross package damage, exposure to high humidity, or freeze-thaw cycles are not part of the qualified distribution envelope. The product should not be returned to stock after opening; if opened, it should be retested for loss on drying, endotoxin, and microbiological quality before use.
Processing limitations should be observed for this grade. The powder should be pre-dried at 40°C under vacuum if loss on drying exceeds 0.5% or if storage RH exceeds 60%. Avoid direct contact with strong oxidizing agents, strong acids, and metal catalysts; compatibility with benzalkonium chloride and other quaternary ammonium preservatives should be evaluated by forced-degradation studies at 40°C/75% RH for 14 days. If the API contains ester or acid-labile functional groups, avoid combination with primary amine buffers because premature degradation may occur. The product is not intended for use in medicated feed requiring thermal pelleting above 85°C unless a stability study demonstrates no assay loss and no polymorph conversion. Published data for this specific configuration are limited; pilot-scale confirmation is recommended for any new route.
